Combining radiofrequency ablation with immunotherapy improves HCC treatment outcomes

Combining radiofrequency ablation (RFA) with immunotherapy shows promising efficacy and manageable safety for hepatocellular carcinoma (HCC). It induces immunogenic substances and regulates immune cell responses, enhancing the anti-tumor immune effects and reconstructing the tumor microenvironment. This synergy reduces the risk of cancer recurrence and metastasis, while also improving overall survival. The findings may provide valuable new strategies for systemic treatment of HCC, which is a significant cause of cancer-related mortality worldwide.